Bacterial vaccine and preparation method thereof

By conjugating Vi-polysaccharides and tetanus toxins of Salmonella typhimurium, ViP-TT vaccine is formed, which solves the problems of insufficient immune response and high injections in children under 2 years old, and achieves the activation of immune responses by a single injection , improves the safety and stability of the vaccine and is suitable for developing countries.

CN112999342BActive Publication Date: 2024-11-15BHARAT BIOTECH INTERNATIONAL LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202110215238.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2013-08-24
Filing Date
2014-08-19
Publication Date
2024-11-15
Estimated Expiration
2034-08-19

AI Technical Summary

Technical Problem

The existing Salmonella typhimurium vaccine cannot elicit an effective immune response in children under 2 years of age, and the number of injections increases the suffering of children and the risks of medical workers. The existing vaccines are not safe in developing countries.

Method used

Vi-polysaccharides of Salmonella typhimurium and tetanus toxins are conjugated to form ViP-TT vaccines, and the batch feed culture and high-pressure homogenization are used for purification and conjugation, reducing the use of linker molecules and improving the stability of the vaccine. and safety, achieving a single injection to elicit an immune response.

Benefits of technology

Achieve T-cell-dependent immune response in children under 2 years old, reduce the number of injections, improve the safety and stability of the vaccine, reduce the risks of children and healthcare workers, is suitable for developing countries, and simplify vaccines Vaccination process.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN112999342B_ABST
    Figure CN112999342B_ABST
Patent Text Reader

Abstract

Disclosed are stable conjugate vaccine formulations for protection against Salmonella typhi, and methods of conjugating the Vi-polysaccharide of Salmonella typhi to tetanus toxoid as a carrier protein, which conjugation results in the generation of an improved T-dependent immune response against typhoid fever caused by Salmonella typhi. The methods disclosed in the present invention and the resulting formulations are capable of inducing immunity against typhoid fever, including in children less than 2 years of age, by only a single injection constituting a complete vaccination schedule.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of an application with a filing date of August 19, 2014, application number 201480057921X, and invention / name “Bacterial vaccine and preparation method thereof”. Field of the Invention

[0002] The present invention relates to the field of bacterial vaccines characterized by eliciting an adequate immune response against typhoid fever in infants, children and adults. In particular, the present invention relates to conjugate vaccines and methods for their preparation, wherein the native polysaccharide of Salmonella typhi is conjugated to a carrier protein and formulated as a prophylactic conjugate vaccine. In addition, the present invention also relates to the field of combined vaccine formulations for protection against Salmonella typhi and measles virus. Background of the Invention

[0003] Salmonella typhi, the pathogenic bacteria of human typhoid fever, is the main endemic disease in Africa, Asia and the Middle East. Food and water contaminated by Salmonella typhi are considered to be the main sources of the disease transmission. Multiple studies have shown that the global burden of typhoid fever is different in different parts of the world. In South-Central Asia and Southeast Asia, more than 100 cases are reported annually in 100,000 populations; It is estimated that Asia, Africa, Latin America and the Caribbean have a medium incidence of typhoid fever, that is, 10 to 100 cases per year in 100,000 populations; New Zealand, Australia and Europe have a low to very low incidence (Crump et al., 2004). This shows that typhoid fever has a strong locality in the region of the world, particularly in developing countries with low resource allocation.

[0004] Salmonella belongs to the Enterobacteriaceae family, which includes Shigella, Escherichia, and Vibrio. The genus Salmonella includes two different species, S. enterica and S. bongori. S. enterica is further divided into six subspecies (enterica, salamae, arizonae, diarizonae, houtenae, and indica) including 2443 serotypes. Thus, the agents that cause typhoid fever are S. enterica subspecies typhi (commonly referred to as S. enterica serotype typhi) and Serotypes A, B, and C of paratyphi. Serovars or serotypes can be defined as strains that have unique surface molecules responsible for the production of specific antibodies. Each serotype has subtle chemical differences in their antigenic regions (Brenner et al., 2000).

[0005] Salmonella typhi has a combination of characteristics that make it a potent pathogen. The species contains endotoxins that are unique to Gram-negative organisms, as well as Vi polysaccharide antigens that are thought to increase virulence. It also produces and secretes a protein called "invasin," which allows non-phagocytic cells to ingest the bacterium, allowing the bacterium to survive intracellularly. It is also able to inhibit the oxidative burst of leukocytes, rendering the innate immune response ineffective. Over the past decade, it has been found that Salmonella species have acquired increasing antibiotic resistance. The reason appears to be the increased and haphazard use of antibiotics in the treatment of salmonellosis in humans and animals, as well as the addition of growth-promoting antibiotics to the food of breeding animals. Antibiotic resistance carried by plasmids is very common in Salmonella strains involved in pediatric epidemics. Resistance to ampicillin, streptomycin, kanamycin, chloramphenicol, tetracycline, ceftriaxone, cefotaxime, cefoperazone, and sulfonamides is often observed. Colistin resistance has not yet been observed. Salmonella strains should be systematically checked for antibiotic resistance to aid in the selection of effective drugs when needed and to detect any changes in the antibiotic sensitivity of strains (from animal or human sources). Until 1972, strains of S. Typhi remained sensitive to antibiotics, including chloramphenicol (the antibiotic most commonly used against typhoid fever); but in 1972, a widespread epidemic in Mexico was caused by chloramphenicol-resistant strains of S. Typhi. Other chloramphenicol-resistant strains have since been isolated in India, Thailand, and Vietnam.

[0006] Vaccines against typhoid fever, caused by Salmonella enterica serovar Typhi, are vital to combat these life-threatening conditions due to the increasing antibiotic resistance. They are also an important means of protection for people traveling to areas where typhoid fever is endemic. Antibiotics may not provide complete protection due to the ability of bacteria to acquire multi-drug resistance. To date, three types of typhoid vaccines have been prepared for use: (1) parenteral killed whole cell vaccines; (2) oral attenuated live vaccines; and (3) Typhoid-Vi capsular polysaccharide vaccines for parenteral use. The cellular and molecular complexity of the organism was clearly studied in the early days and vaccines against typhoid fever were designed. Initially, whole cell Salmonella enterica serovar Typhi that was inactivated by heat-phenol-inactivation for parenteral administration was used as a vaccine, administered in two doses. Since whole cell killed vaccines contain the 'O' antigen (endotoxin), they tend to produce local and systemic reactions in the vaccinated individual, and these types of vaccines require booster doses every two years. Oral attenuated live Ty21a vaccine is considered to be a second generation vaccine, which is made using mutant Salmonella typhi strains lacking adenylate cyclase and AMP receptor proteins and mutants of para-aminobenzoate / ester and adenine auxotrophy. These attenuated live vaccines report poor efficacy and are found to be unsuitable for use in children less than 6 years old. In addition, booster doses are required every 5 years. Later, the capsule Vi-polysaccharide of Salmonella typhi was identified as a protective immunogen that can cause sufficient immune response in humans, and is therefore used as a potential vaccine candidate in the routine immunization schedule. The purified capsule Vi-polysaccharide (ViP) injected with a dose of 25 μg / 0.5 mL can produce the maximum seroconversion, that is, the antibody rises to four times. However, in many clinical trials, the limitations of Vi-polysaccharides have been reported, and natural polysaccharide vaccines cannot or do not produce a second immune response. This phenomenon is due to the fact that bacterial polysaccharides are actually T cell-independent, and therefore cannot produce a cell-mediated immune response. Therefore in order to solve the problem, further conjugate the polysaccharide and carrier protein of Salmonella typhi to form polysaccharide-protein molecule, so that it becomes T cell dependent antigen.There are multiple factors that affect polysaccharide and protein combination, and the combination depends on the molecular weight of selected ViP and carrier protein and the activation of functional groups.Low molecular weight polysaccharide can cause effective combination with carrier protein.Multiple carrier proteins like tetanus toxoid, diphtheria CRM197, the B subunit (LT-B) of the heat labile toxin of Escherichia coli (Escherichia coli), the recombinant extracellular protein A (rEPA) of Pseudomonas aeruginosa (Pseudomonas aeruginosa) and horseshoe rab hemocyanin (Horseshoe rab Haemocyanin) (HCH) have been often used for conjugation.

[0007] WO1996 / 011709 discloses an O-acetylated oligonucleotide or polygalacturonate pectin, which is substantially identical to the Vi polysaccharide subunit structure conjugated to a carrier protein tetanus toxoid, wherein the carrier protein is derived from cystamine. This particular patent teaches the use of different derivatizers, namely cystamine, to conjugate the same polysaccharide, rather than the Vi-polysaccharide, to a carrier protein. Later, WO1998 / 026799 discloses a lipopolysaccharide separated from Salmonella paratyphi A, which has been detoxified to remove its lipid A and retains 70% to 80% of its O-acetyl content, and is then conjugated to the carrier protein tetanus toxoid by adipic acid dihydrazide (ADH). WO2000 / 033882 discloses a Vi-polysaccharide (Vi-rEPA) conjugate of Salmonella typhi covalently bound to a protein of Pseudomonas aeruginosa by adipic acid dihydrazide. WO2007 / 039917 discloses exogenous antigens of Salmonella typhi that are covalently / non-covalently bound to heat shock proteins.

[0008] WO2009 / 150543 describes a conjugated Vi-polysaccharide, which is used as a vaccine composition against Salmonella typhi causing typhoid fever, wherein the Vi-polysaccharide is covalently conjugated to a protein selected from CRM197 or tetanus toxoid. The conjugation method disclosed in WO2009 / 150543 includes first adding a carrier protein (preferably CRM197 or tetanus toxoid) to a linker (such as adipic acid dihydrazide (ADH)) and a carbodiimide (such as 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDAC)) in the presence of 2-(N-morpholino)ethanesulfonic acid (MES buffer) to obtain a derived carrier protein. The weight ratio of carbodiimide EDAC to carrier protein is between 0.1 and 0.15. It also discloses that a higher amount of carbodiimide / protein ratio can cause aggregate formation. Activation of the Vi-polysaccharide (ViP) is also performed after derivatization of the carrier protein. The Vi-polysaccharide is also activated with carbodiimide, where various ratios of ViP and carbodiimide (EDAC) are mixed to activate the Vi-polysaccharide. It is mentioned that Vi activation can be performed at room temperature within two minutes, where higher ratios between 1.5:1 and 200:1 can be used. The derivatized carrier protein CRM197 or tetanus toxoid and the activated Vi-polysaccharide of Salmonella typhi are then reacted with each other to obtain a conjugated ViP-CRM197 or ViP-TT conjugate, and then the excess linker is removed.

[0009] In 1999, Zuzana Kossaczka et al. evaluated the safety and immunogenicity of ViP conjugate vaccine in adults, adolescents and children aged 2 to 4 years in Vietnam. In this study, the geometric mean level of anti-Vi-rEPA (conjugate vaccine) in children aged 2 to 4 years was higher than that caused by Vi capsular polysaccharide vaccine in children aged 5 to 14 years. In children aged 2 to 4 years, re-injection of conjugate vaccine caused an increase in antibody titers (T cell dependent). Konadu et al. (2000) prepared O-specific polysaccharide (O-SP) of Salmonella paratyphi A and conjugated it to tetanus toxoid. These conjugates induced IgG antibodies in mice, and the safety and immunogenicity of the conjugates were evaluated in Vietnamese adults, adolescents and children aged 2-4 years. The study concluded that these experimental conjugates were safer and confirmed to induce IgG antibodies in adults, adolescents and children aged 2-4 years. Feng Ying C et al. evaluated the efficacy of Salmonella typhi ViP conjugate vaccine in children aged 2 to 5 years. In this study, the conjugate typhoid vaccine was found to be safe and immunogenic, and had an efficacy of more than 90% in children aged 2 to 5 years. In 36 children evaluated, serum IgG Vi antibodies increased to 10 times after the second dose level at six weeks. These cases lasted for a period of 27 months. No serious adverse reactions due to vaccination were observed in this study. Do Gia Canh et al. studied the effect of dose on the immunogenicity of ViP conjugate vaccines injected twice into Vietnamese children aged 2 to 5 years. In this study, the dose immunogenicity study of 5μg, 12.5μg and 25μg conjugate vaccines injected twice 6 weeks apart was evaluated. This study also confirmed safety and the consistent immunogenicity of four groups of conjugate vaccines in this trial and previous trials. Novartis Vaccine Institute for Global Health implemented three different dose-related ViP-CRM197 formulations. The different doses they implemented were 25μg / dose, 12.5μg / dose, 5μg / dose and 1.25μg / dose. On day 28, these concentrations of GMT were 304 U (units), 192 U, 111 U, and 63 U, respectively. On day 28 after a single injection, 25 μg / dose of GMT induced the highest antibody level (304 U).

[0010] Although the current state of the art includes conjugate vaccines with Vi-polysaccharide and carrier protein, existing natural Vi-polysaccharide conjugate vaccines show when tested in many human clinical trials that these vaccines are safe and immunogenic in adults, but can not cause any protective immune response in children less than 2 years old. Therefore, it has been confirmed that this natural Salmonella typhi polysaccharide vaccine can not find any special solution for the lethal Salmonella typhi infection less than 2 years old children, which requires a new vaccine that can make the children's immunity resistance less than 2 years old responsible for causing typhoid infection of Salmonella typhi. The age group less than 2 years old is most susceptible to infection by Salmonella typhi, but it seems that there is no available protective vaccine for human beings less than 2 years old infants and young children to resist Salmonella typhi so far. As discussed above, a variety of carrier proteins such as CRM-197, r-EPA, have been conjugated to Vi-polysaccharide, wherein the Vi-polysaccharide may not yet be separated from Salmonella typhi, or not yet described from any other source. Thus, the production of typhoid conjugate vaccines is specific to the particular carrier protein and native polysaccharide involved in the conjugation process as well as the resulting conjugate vaccine. Each carrier protein-polysaccharide conjugation lends itself to a different conjugate vaccine identity. The prior art, methods disclosed in the field of typhoid conjugate vaccines and those currently in use, have their own shortcomings, which may be the possible reason behind the absence of any currently available conjugate vaccine capable of protecting children less than 2 years of age.

[0011] It is also very clear and well known in the current state of the art that current typhoid conjugate vaccines require at least 2 or more injections with a 6-8 week interval to complete a vaccination schedule. BioMed prepares a publicly available Typhoid Vi Capsular Polysaccharide-Tetanus Toxoid (ViP-TT) conjugate vaccine, so the conjugate vaccine requires 2 injections of 5 μg each with a 6-8 week interval to complete a single vaccination schedule. However, this ViP-TT vaccine is also unable to immunize children under two years old against Salmonella Typhi. SUMMARY OF THE INVENTION

[0012] Therefore, there is a need for changing the conjugation method to reduce costs and reduce the number of injections to only one injection to induce a sufficient immune response, as well as other related technical problems in the field of conjugation chemistry that will be simpler, less time-consuming, cost-effective and safe. An effective vaccine must be able to induce a good immune response and must be suitable for use in infants, especially infants less than two years old. The disclosure as described in the present invention is attributed to a novel optional method of conjugating Vi-polysaccharides with a specific carrier protein tetanus toxoid (TT) in an inventive manner shown in this application, which potentially overcomes the shortcomings of natural polysaccharide vaccines, as well as current conjugation methods, including other ViP vaccines conjugated to carrier proteins. The Vi-polysaccharide-protein conjugate vaccine produced by this specific method shown in this patent application makes it more suitable for immunization in children and infants less than two years old, with secondary memory responses, and produces high-affinity antibodies against Salmonella typhi infection, including humans of any age group. Yet another advantage of the invention proposed in the present application is that the number of injections of the typhoid conjugate vaccine to complete the vaccination schedule has also been reduced to only one, while at the same time eliciting a better immune response when compared to the immune response produced by the previously practiced vaccination schedule of two or three injections of the typhoid conjugate vaccine. A single injection of the typhoid conjugate vaccine has always been preferred for infants and children as it reduces the suffering of the child or infant from additional visits to the clinic, repeated injections for vaccination. It has been reported that 40% of injections worldwide are administered using non-sterile, reused syringes and needles, and especially in developing countries that are the target of attack, the proportion is higher than 70%, exposing millions of people to infections where pathogens enter the tissues of the body during the injection. In addition, poor collection and disposal of dirty injection devices exposes health care workers and the community to the risk of needle stick injuries. Unfortunately, in some countries, unsafe disposal also leads to the resale of used devices on the black market. Open burning of syringes is unsafe under the WHO, but half of the non-industrialized countries in the world still practice this practice. (“Injection safety”, Health Topics A to Z. World Health Organization. Retrieved 2011-05-09.). Unsafe injections cause an estimated 1.3 million premature deaths each year. (MA Miller & E. Pisani. “The cost of unsafe injections”. Bulletin of the World Health Organization 77(10):1808–811).Although, in order to improve injection safety, WHO recommends the use of certain alternatives to injections, depending on the situation, by assisting in ensuring the availability of equipment and supplies with safe and appropriate management of waste, otherwise controlling and regulating the activities of health-care workers and patients, vaccine recipients; these measures are not always possible to be fully observed. In such cases, the combination of typhoid conjugate and measles vaccines in a single injection will certainly play an important role in reducing the concerns related to injection safety in national immunization programs. Many countries do have laws or policies that mandate health-care professionals to use safe syringes (safety-designed needles) or alternative methods of administering drugs whenever possible, but, from a public health point of view, reducing the number of injections to ensure protection against typhoid and measles in infants and young children with a single injection, undoubtedly implies high compliance, since previously at least 3 injections were required to administer the typhoid (minimum 2 injections) and measles (one injection) vaccines, now the same goal can be achieved with only one injection.

[0013] Invention goal

[0014] The primary objective of the present invention is to develop a vaccine formulation for the prevention and treatment of Salmonella typhi infections in humans such that the T-independent polysaccharide can be made T cell dependent, thereby promoting an effective immune response in all age groups, especially children less than 2 years old, and also in adults.

[0015] Another object of the present invention is to provide a vaccine composition against fever caused by Salmonella typhi having a suitable conjugate polysaccharide as vaccine antigen which will confer protection to children less than 2 years old.

[0016] It is an object of the present invention to provide a fed-batch process for the production of Vi capsular polysaccharides.

[0017] It is a further object of the present invention to provide a method for conjugating size-reduced or non-size-reduced Vi capsular polysaccharide to a carrier protein.

[0018] Yet another object of the present invention is to provide an alternative method, an efficient conjugation method to increase the conjugation percentage between Vi polysaccharide and carrier protein by reducing the size of ViP of Salmonella typhi prior to conjugation with the carrier protein in a reduced time.

[0019] Still another object of the present invention is to provide a method for conjugating the Vi capsular polysaccharide of Salmonella typhi and the carrier protein tetanus toxoid with or without the use of a linker molecule as a final polysaccharide conjugate stock solution and finished vaccine.

[0020] A further object of the present invention is to provide an immunogenic vaccine formulation comprising a coupled polysaccharide-protein conjugate of Vi-polysaccharide-protein in suitable single-dose and multi-dose vials which will be administered in infants and adults at a suitable concentration effective to confer protection against Salmonella typhi.

[0021] According to one embodiment of the present invention, the cultivation and processing of Salmonella typhi Vi-polysaccharide is disclosed. It is further purified through several downstream processing steps to obtain pure Vi-polysaccharide.

[0022] According to another embodiment of the present invention, a method for conjugating pure Vi-polysaccharide to a conjugate with a protein tetanus toxoid in the presence of a linker molecule adipic acid dihydrazide (ADH) is disclosed. The yield of the obtained pure ViP-TT conjugate is as high as 70%-80%.

[0023] According to another alternative embodiment of the present invention, a method for conjugating Vi-polysaccharide to a conjugate with a protein tetanus toxoid in the absence of any linker molecule is disclosed. The yield of the obtained pure ViP-TT conjugate without a linker is as high as 70%-80%.

[0024] Further embodiments of the present invention disclose stable formulations of ViP-TT conjugate vaccines having appropriate concentration of ViP-TT to ensure a complete vaccination schedule with only one injection, along with ViP-TT, with or without 2-phenoxyethanol as a preservative.

[0025] Another embodiment of the present invention provides clinically definitive experimental data of a stable ViP-TT conjugate vaccine formulation that exhibits strong seroprotection and elicits the desired immunogenicity against Salmonella Typhi infection in humans, including infants less than 2 years old (6 months to 2 years old) and subjects of other age groups, through only one injection constituting a complete vaccination schedule.

[0026] This application provides the following:

[0027] 1). A vaccine formulation for preventing typhoid fever caused by Salmonella typhi, comprising as vaccine antigen the capsular Vi-polysaccharide (ViP) of Salmonella typhi, conjugated to a carrier protein, wherein the vaccine formulation is sufficient to induce the desired T-dependent immune response against Salmonella typhi, including in children less than 2 years of age, by only one injection constituting a complete vaccination schedule.

[0028] 2). The vaccine formulation according to 1), wherein the vaccine antigen is present in a concentration of 5 μg to 25 μg per dose, preferably 25 μg per dose.

[0029] 3). The vaccine preparation according to 1), wherein the carrier protein is selected from tetanus toxoid, diphtheria toxoid, CRM197, preferably tetanus toxoid.

[0030] 4). The vaccine preparation according to 1), wherein the vaccine antigen is prepared by a method comprising the following steps:

[0031] a. Cultivating in a fed-batch mode using a feed medium comprising feeding a solution containing glucose in a concentration range of 1 mg / mL to 2 mg / mL, maintaining pH in the range of 6.90 to 7.20 and maintaining dissolved oxygen level between 40% and 60%, wherein together with the feed medium, an ammonia solution (50%) is supplied as a nitrogen source;

[0032] b. Optionally reducing the size of ViP, wherein said ViP at a concentration of 5-7.5 mg / ml is subjected to high pressure homogenization at 1500 bar at 2-8° C. and the same activity is repeated at least 45 times, or by microwave oven, to obtain a purified ViP of a corresponding molecular size of approximately 250 kDa;

[0033] c. treating the purified ViP of step (a) or step (b) with a cross-linking agent EDAC;

[0034] d. activating the ViP of step (c) with the linker molecule ADH in the presence of EDAC;

[0035] e. treating the activated ViP linked to the linker molecule ADH of step (d) with a carrier protein in the presence of EDAC at a concentration of 1 mg / ml to 5 mg / ml of purified ViP of ˜900 kDa or at a concentration of 5 mg / ml to 7.5 mg / ml of purified ViP of ˜250 kDa to form a Vi-polysaccharide-carrier protein conjugate;

[0036] f. Diafiltration of the Vi-polysaccharide-carrier protein conjugate of step (f) was performed by continuous buffer exchange with phosphate buffered saline using a 1000 kDa membrane to obtain purified ViP-carrier protein vaccine antigen.

[0037] 5). The vaccine preparation according to 1, wherein the vaccine antigen is prepared by a method comprising the following steps:

[0038] a. Cultivating in a fed-batch mode using a feed medium comprising feeding a solution containing glucose in a concentration range of 1 mg / mL to 2 mg / mL, maintaining pH in the range of 6.90 to 7.20 and maintaining dissolved oxygen level between 40% and 60%, wherein together with the feed medium, an ammonia solution (50%) is supplied as a nitrogen source;

[0039] b. Optionally reducing the size of ViP, wherein said ViP at a concentration of 5-7.5 mg / ml is subjected to high pressure homogenization at 1500 bar, 2-8° C. and the same activity is repeated at least 45 times, or by microwave oven, to obtain a purified ViP of a corresponding molecular size of approximately 250 kDa;

[0040] c. treating the purified ViP of step (a) or step (b) with a cross-linking agent EDAC;

[0041] d. treating the carrier protein with the ViP of step (c) in the presence of the cross-linking agent EDAC at a concentration of 1 mg / ml to 5 mg / ml of purified ViP of ˜900 kDa or at a concentration of 5 mg / ml to 7.5 mg / ml of purified ViP of ˜250 kDa to form a Vi-polysaccharide-carrier protein conjugate;

[0042] e. Diafiltration of the Vi-polysaccharide-carrier protein conjugate of step (d) was performed by continuous buffer exchange with phosphate buffered saline using a 1000 kDa membrane to obtain purified ViP-carrier protein vaccine antigen.

[0043] 6). The vaccine preparation according to 4) and 5), wherein the carrier is tetanus toxoid.

[0044] 7). A method for preparing a Salmonella typhi Vi-polysaccharide-carrier protein conjugate vaccine antigen, the method comprising the following steps:

[0045] a. Cultivating in a fed-batch mode using a feed medium comprising feeding a solution containing glucose in a concentration range of 1 mg / mL to 2 mg / mL, maintaining pH in the range of 6.90 to 7.20 and maintaining dissolved oxygen level between 40% and 60%, wherein together with the feed medium, an ammonia solution (50%) is supplied as a nitrogen source;

[0046] b. Optionally reducing the size of ViP, wherein the ViP at a concentration of 5-7.5 mg / ml is subjected to high pressure homogenization at 1500 bar, 2-8° C. and the same activity is repeated at least 45 times, or by microwave oven, to obtain a purified ViP of a corresponding molecular size of approximately 250 kDa;

[0047] c. treating the purified ViP of step (a) or step (b) with a cross-linking agent EDAC;

[0048] d. activating the ViP of step (c) with the linker molecule ADH in the presence of EDAC;

[0049] e. treating the activated ViP linked to the linker molecule ADH of step (d) with a carrier protein in the presence of EDAC at a concentration of 1 mg / ml to 5 mg / ml of purified ViP of ˜900 kDa or at a concentration of 5 mg / ml to 7.5 mg / ml of purified ViP of ˜250 kDa to form a Vi-polysaccharide-carrier protein conjugate;

[0050] f. Diafiltration of the Vi-polysaccharide-carrier protein conjugate of step (f) was performed by continuous buffer exchange with phosphate buffered saline using a 1000 kDa membrane to obtain purified Vi-polysaccharide-carrier protein vaccine antigen.

[0051] 8). A method for preparing a Salmonella typhi Vi-polysaccharide conjugate vaccine antigen, the method comprising the following steps:

[0052] a. Cultivating in a fed-batch mode using a feed medium comprising feeding a solution containing glucose in a concentration range of 1 mg / mL to 2 mg / mL, maintaining pH in the range of 6.90 to 7.20 and maintaining dissolved oxygen level between 40% and 60%, wherein together with the feed medium, an ammonia solution (50%) is supplied as a nitrogen source;

[0053] b. Optionally reducing the size of ViP, wherein said ViP at a concentration of 5-7.5 mg / ml is subjected to high pressure homogenization at 1500 bar, 2-8° C. and the same activity is repeated at least 45 times, or by microwave oven, to obtain a purified ViP of a corresponding molecular size of approximately 250 kDa;

[0054] c. treating the purified ViP of step (a) or step (b) with a cross-linking agent EDAC;

[0055] d. treating the carrier protein with the ViP of step (c) in the presence of the cross-linking agent EDAC at a concentration of 1 mg / ml to 5 mg / ml of purified ViP of ˜900 kDa or at a concentration of 5 mg / ml to 7.5 mg / ml of purified ViP of ˜250 kDa to form a Vi-polysaccharide-carrier protein conjugate;

[0056] e. Diafiltration of the ViP-carrier protein conjugate of step (d) was performed by continuous buffer exchange with phosphate buffered saline using a 1000 kDa membrane to obtain purified ViP-carrier protein vaccine antigen.

[0057] 9). The vaccine formulation according to any one of 7) and 8), wherein the carrier protein is tetanus toxoid.

[0058] 10). The vaccine formulation according to any one of 4) to 9), wherein the molecular size of the ViP-carrier protein conjugate molecule ranges from 0.25 kDa to 0.35 kDa.

[0059] 11). The vaccine formulation according to any one of 1), 4) and 5), wherein the yield of the conjugate ViP-carrier protein molecules ranges from 70% to 80%.

[0060] 12). The method according to any one of 7) and 8), wherein the yield of the conjugate ViP-carrier protein molecules ranges from 70% to 80%.

[0061] 13) A method comprising preventing typhoid fever caused by Salmonella Typhi in children less than 2 years of age by administering a vaccine preparation, said prevention being by only one injection constituting a complete vaccination schedule, wherein said vaccine preparation comprises a Salmonella Typhi Vi polysaccharide conjugated to a carrier protein tetanus toxoid, said vaccine preparation being sufficient to elicit the desired T-dependent immune response against Salmonella Typhi.

[0062] 14). The method according to 13, wherein the vaccine antigen is present in a concentration of 5 μg to 25 μg per dose, preferably 25 μg per dose.

[0063] 15). The vaccine formulation according to 1) or the method according to 13), wherein the vaccine formulation is stable at 2°C-8°C for 3 years and is stable at 25°C for at least 6 months.

[0064] 16). The vaccine formulation according to 1) or the method according to 13), wherein the vaccine formulation further comprises 2-phenoxyethanol as a stabilizer in the case of a multi-dose vial.

[0065] 17). The vaccine formulation according to 1) or the method according to 13), wherein the seroconversion % of the vaccine formulation is between 98% and 100% in the age group of 6 months to 24 months, between 99% and 100% in the age group of 2 years to 15 years, and between 90% and 100% in 92.13% of the age group, thereby providing a four-fold increase in seroconversion on day 42 after vaccination.

[0066] 18). The vaccine preparation according to 1), wherein the vaccine preparation is used as a reconstituted product with a measles vaccine preparation, and there is no antigenic interference between the Vi polysaccharide-tetanus toxoid conjugate antigen and the measles antigen.

[0067] 19). A combined vaccine preparation comprising the following antigens:

[0068] a. Salmonella typhi Vi-polysaccharide-tetanus toxoid (Vip-TT) conjugate antigen;

[0069] b. Measles antigen;

[0070] There is no antigenic interference between ViP-TT and measles antigens for the prevention of typhoid fever caused by Salmonella Typhi and measles virus, and wherein the vaccine formulation is sufficient to induce the desired T-dependent immune response against Salmonella Typhi by only one injection constituting a complete immunization schedule, including in children less than two years of age.

[0071] 20). The combined vaccine formulation according to 19), wherein the vaccine antigen is present in a concentration of 5 μg to 25 μg per dose, preferably 25 μg per dose. BRIEF DESCRIPTION OF THE DRAWINGS

[0072] Figure 1 : General scheme for the production and conjugation of ViP using the linker AHD (left side) and without a linker (right side).

[0073] Figure 2 : Serological identification test for Vi polysaccharide.

[0074] Figure 3 : HPLC of native Vi-polysaccharide of Typhus, HP-GPC column spectrum of purified Vi-polysaccharide analyzed by RI detector. The peak at 13.185 minutes represents native Vi-polysaccharide, which indicates a molecular weight of ~900 kDa.

[0075] Figure 4 : Size-reduced ViP was performed using a homogenizer for approximately 45 passes. HP-GPC column spectrum of size-reduced Vi-polysaccharide was analyzed by RI detector. The peak at 16.04 minutes represents size-reduced Vi-polysaccharide, which indicates a molecular weight of ~200 kDa.

[0076] Figure 5 : Size reduced ViP using microwave oven. HP-GPC column spectrum of size reduced Vi-polysaccharide analyzed by RI detector. The peak at 15.18 minutes represents size reduced Vi-polysaccharide which indicates a molecular weight of -250 kDa.

[0077] Figure 6 : HPLC (RI) of ViP-TT conjugate stock solution. HPLC spectrum of Vi-polysaccharide-tetanus toxoid conjugate detected by RI detector using HP-GPC column. The peak at 12.83 minutes represents the conjugate ViP-TT with linker molecule.

[0078] Figure 7 : HPLC (UV) of ViP-TT conjugate stock solution. HPLC spectrum of Vi-polysaccharide-tetanus toxoid conjugate detected by UV detector using HP-GPC column. The peak at 12.66 minutes represents the conjugate ViP-TT with linker molecule.

[0079] Figure 8 : HPLC (RI) of ViP-TT conjugate stock solution without linker. HPLC spectrum of Vi-polysaccharide-tetanus toxoid conjugate vaccine detected by RI detector using HP-GPC column. The peak at 12.98 minutes represents the conjugate ViP-TT conjugate without linker.

[0080] Fig. 9 : HPLC (UV) of ViP-TT conjugate stock solution without linker. HPLC spectrum of Vi-polysaccharide-tetanus toxoid conjugate vaccine detected by UV detector using HP-GPC column. The peak at 12.662 minutes represents the conjugate ViP-TT conjugate without linker.

[0081] Fig.10 : HPLC (RI) of ViP-TT conjugate vaccine. HPLC spectrum of Vi-polysaccharide-tetanus toxoid conjugate vaccine detected by RI detector using HP-GPC column. The peak at 12.82 minutes represents the conjugate ViP-TT conjugate.

[0082] Fig.11 : HPLC (UV) of ViP-TT conjugate vaccine. HPLC spectrum of Vi-polysaccharide-tetanus toxoid conjugate vaccine detected by UV detector using HP-GPC column. The peak at 12.72 minutes represents the conjugate ViP-TT conjugate.

[0083] Fig.12 : Comparison of geometric mean titers in different age groups after a single injection of 25 μg of ViP-TT conjugate vaccine.

[0084] Fig.13 : Comparison of % seroconversion in different age groups after a single injection of 25 μg of ViP-TT conjugate vaccine. DETAILED DESCRIPTION OF THE INVENTION

[0085] Salmonella typhi is grown in a suitable culture medium, and the actively growing cells are transferred to a fermentor tank containing a pre-sterilized culture medium. Initially, the fermentation process of batch mode is carried out, and after the culture reaches the early stable stage, the feed medium containing a high concentration of carbon source is pumped incrementally into the fermentor tank. The fermentation process of batch feed mode is carried out until the optical density desired is obtained. Culture is harvested by deactivating formalin with low concentration, and then centrifuged to obtain cell supernatant. Hexadecyl trimethylammonium bromide (Cetavlon) is added to the cell supernatant to precipitate crude Vi-polysaccharide from the host cell component. Purification steps are carried out in sequence, i.e., ethanol precipitation, using different molecular weight cut-off membranes and aseptic filtration techniques to concentrate and diafiltration, so that the Vi-polysaccharide of purification is separated from host cell impurities such as nucleic acid, protein and lipopolysaccharide.

[0086] The factors that affect the coupling of polysaccharides and proteins depend on the activation of molecular weight and functional groups. Low molecular weight polysaccharides can lead to effective coupling. Different proteins such as tetanus toxoid, diphtheria CRM197, the B subunit (LT-B) of the heat-labile toxin of Escherichia coli, the recombinant exoprotein A (rEPA) of Pseudomonas aeruginosa and horseshoe rab hemocyanin have been commonly used for conjugation. Determining the molecular size of polysaccharides and polysaccharide-protein conjugates of bacterial polysaccharides is an important aspect in designing conjugate vaccines. The evaluation of the physicochemical properties of polysaccharide-protein conjugates plays an important role in eliciting specific immune responses. Determining the molecular size of polysaccharides before and after conjugation leads to effective conjugation. Two important key quality control tests adopted after conjugation and purification are 'the ratio of polysaccharide (PS) to protein' and 'the percentage of unconjugated polysaccharides (free polysaccharides)'.

[0087] Podda et al. (2010) reported the epidemiology and importance of immunization in children less than two years of age. Currently available vaccines have some corresponding limitations and therefore cannot be used in children less than two years of age, an age group affected by a significant burden of typhoid fever. The introduction of conjugate vaccines is expected to be an effective means to effectively immunize all age groups, but there is currently no available experimental data that can immunize typhoid conjugate vaccines at ages less than 2 years old. The present invention, relying on its unique conjugation method of ViP-TT conjugate vaccine, has the following advantages: it is possible to immunize children or infants less than two years of age from infection with Salmonella Typhi that causes typhoid fever in this young age group, which is accordingly supported by experimental clinical trial data, and also reduces the number of injections in infants less than two years of age to complete the complete vaccination schedule with only one dose of typhoid conjugate vaccine.

[0088] Example 1: Cultivation and treatment of Salmonella typhi Vi polysaccharide

[0089] The strain Salmonella typhi (Ty2) was obtained from Dr. John Robbins of the National institutes of Child Health and Human Development (NICHD), USA. The culture obtained from NICHD, USA was confirmed and identified as Salmonella typhi serotype by the following characteristics: Gram stain, glucose positive without gas production, H on xylose lysine deoxycholate agar (XLD agar). 2 S-positive and Vi-positive serology for polysaccharide. The purity of the strain was verified on different selective media such as bismuth sulfite agar (BSA), triple sugar iron (TSI) agar. The purity of the strain was verified on different selective media such as xylose lysine deoxycholate agar (XLD agar), bismuth sulfite agar (BSA), triple sugar iron (TSI) agar.

[0090] Salmonella typhi Ty2 was grown on soybean casein digest (SCDM) medium at 37 ± 1 ° C for 12 hours. The bacterial culture was centrifuged and the pellet was resuspended in sterile glycerol (50%). A glycerol suspension of 0.5 mL aliquots in a 1 mL cryovial was prepared and stored at -70 ° C. The viable cell count of the master seed was also performed. The contents of the cryovial of the master seed batch were inoculated into SCDM liquid culture medium and incubated at 37 ± 1 ° C for 12 hours. The bacterial culture was centrifuged and the pellet was resuspended in sterile glycerol (50%). Viable cell count was performed. A glycerol suspension aliquot in a cryovial was prepared and stored at -70 ° C. The master cell bank and working cell bank were characterized by Gram staining, utilization of glucose (Durham method), oxidase test, agglutination test and viable cell count. It was plated on tryptone soy agar (TSA) and incubated at 37 ° C for 48 to 72 hours. Count the colonies using a colony counter.

[0091] 1.1 Fermentation process:

[0092] Inoculum cultivation: take out the content of the working seed batch of a freezing tube from refrigerator, and use water bath to thaw at room temperature.To be inoculated in 10mL soybean casein digestion medium (SCDM) from a freezing tube of the working cell bank of Salmonella typhi, and cultivate 12 hours (stage-I) at 37 ± 1 ℃, transfer to two flasks containing 50mL SCDM separately, 37 ± 1 ℃ continues 12 hours (stage-II), and finally transfer to four flasks containing 400mL SCDM separately and hatch 12 hours (stage-III) at 37 ± 1 ℃.In each stage of culture transfer, purity and morphological characteristics are checked by Gram staining.Check OD at 600nm.The OD of the Salmonella typhi culture recorded at the different stages of seed growth changes to 3.8 from 1.2.

[0093] Batch mode fermentation:

[0094]

[0095] Table 1.1 Fermentation parameters and specification limits

[0096] First, 85L of SCDM was prepared in a 100L SS container and transferred to a fermentor. Sterilized in situ at 121°C for 15 minutes. The culture medium was cooled to 37°C. The supplementary mixture was pumped into the fermentor through the injection port at this stage. In order to maintain pH, a 50% ammonia solution in the bottle was connected to the injection port as a nitrogen source. The seed inoculum was transferred to the fermentor and the fermentation process was carried out at a pH of 6.9 ± 0.2, a temperature of 37 ± 2°C, and dissolved oxygen was maintained at 70-90%, for a period of up to 22 to 24 hours. Growth was checked by measuring the OD value at 600nm initially at 0 hour and every 2 hours until 24 hours.

[0097] Fed-batch fermentation: Fed-batch fermentation of Salmonella typhi resulted in increased production of Vi polysaccharide. 600 Phase III cultures with a pH of 3.8 are ideal for fermentation. The pH is maintained at 6.90 and the dissolved oxygen level is between 40% and 60%. Throughout the fermentation process, until the early stationary phase culture, the feed medium containing the carbon source is pumped incrementally into the fermentor along with inorganic salts and minerals. A fed batch fermentation method is used herein to increase biomass by feeding a solution containing glucose in a concentration range of 1 mg / mL to 2 mg / mL. The pH is maintained in the range of 6.90 to 7.20, and the dissolved oxygen level is maintained between 40%-60%. Along with the feed medium, an ammonia solution (50%) is supplied as a nitrogen source. Foaming is controlled by aseptically pumping an antifoam solution through the injection port. 10% NH 4OH maintained an optimum pH of 7.2 and the concentration of dissolved oxygen was maintained at 35% of air saturation. Glucose levels were monitored every 30 minutes and maintained at approximately 1 g / L throughout the process by a fed-batch method.

[0098] The process lasts until 24 hours, and then the bacterial culture is inactivated with 0.5% formaldehyde and maintained under refrigerated conditions (below 15°C) under gentle stirring. Growth is checked by measuring the OD value at 600nm at 0 hour and every 2 hours for 24 hours. This feeding strategy results in an increase in biomass, reaching about 120 to 130 in terms of optical density. The increased biomass is converted into larger Vi polysaccharide production, which in the present process achieves a final yield of about 1000 mg of Vi-polysaccharide per liter in fed batch culture, and 400 mg of purified ViP per liter is finally obtained from the process after completing the downstream process. Therefore, the batch feeding culture mode results in a final yield of at least 40%.

[0099] 1.2. Downstream Processing of Purified Vi Polysaccharide Stock (ViP)

[0100] The fermentation cell supernatant is subjected to different purification steps to isolate the purified Vi-polysaccharide. Vi-polysaccharide consists of repeating units of 2-acetylamino-2-deoxy-d-galacturonic acid partially 3-O-acetylated with α-(1→4) bonds. Therefore, determining the O-acetyl content can be associated with the amount of Vi-polysaccharide. The final pure Vi-polysaccharide fraction should contain 2mM of O-acetyl per gram of Vi-polysaccharide (WHO TRS 840). The supernatant usually contains a large amount of protein, nucleic acid and lipopolysaccharide. Filtration technology plays an important role in the downstream process of purifying bacterial polysaccharides from host cell impurities. The desired molecules are retained from the dissolved substances based on size; particles with larger sizes will be retained on the surface, and those particles with lower nominal molecular weight limit (NMWL) than the membrane will flow out during the permeation process (Jagannathan et al., 2008). A 100 kDa cut-off cassette was used in the initial cell supernatant concentration step and a 300 kDa cut-off cassette was used in the final concentration step and diafiltration was performed using sterile water for injection (WFI).

[0101] Cell separation: Centrifuge the harvested culture at 9000 rpm (8000 g) for 30 minutes at 4°C in a bowl centrifuge. Collect the supernatant in a sterile container. Obtain a sample from the supernatant and determine the O-acetyl content.

[0102] Concentration and diafiltration: The supernatant was diafiltered by using a tangential flow filtration (TFF) system using a 100 kDa membrane. The supernatant was concentrated to 1 / 10 of the initial volume and further diafiltered with water for injection (WFI) until the desired concentration was obtained. The O-acetyl content of the concentrate was determined.

[0103] Cetrimide precipitation: Add 0.4 M cetrimide to the concentrate and incubate at (5°C ± 1°C) for 3 ± 1 hours. Centrifuge the contents at 9000 rpm for 30 minutes at 4°C. Suspend the collected pellet in the required volume of 1 M NaCl. Determine the O-acetyl content of the pellet suspension.

[0104] Ethanol precipitation: One volume of ethanol and 2% sodium acetate were added to the resuspended cetrimide precipitate; the contents were stirred for 20 ± 5 minutes using a magnetic stirrer. The contents were centrifuged at 4200 rpm (8000 g) for 30 minutes at 4°C. The supernatant was collected in a sterile bottle and the pellet was discarded. Two volumes of ethanol (100%) were added to the supernatant under continuous stirring for a period of 60 ± 10 minutes. 2% sodium acetate was added to the above contents under continuous stirring. After incubation for 1 hour, the contents were centrifuged at 4200 rpm (8000 g) for 30 minutes at 4°C. The supernatant was discarded; the pellet was suspended in sterile cold WFI and transferred to a sterile bottle. The samples were tested for O-acetyl content. Filtration: The concentrated ViP stock solution was passed through a 0.22μ capsule filter (Sartopore, Sartorius). The O-acetyl content of the sterile filtered purified ViP stock solution was determined. The ViP stock solution thus obtained was re-extracted with cetrimide and precipitated with ethanol. Finally, the stock solution was concentrated and diafiltered using a 300 kDa cartridge (referred to as concentrated stock solution) as mentioned above. The O-acetyl content was measured after each process. The following O-acetyl content of the different steps of the downstream process as given in the following table 1.2 was obtained. The O-acetyl content was analyzed by the Hestrin method as described below.

[0105] Determination of O-acetyl content: The determination of O-acetyl content was performed by the method of Hestrin (Hestrin, 1949). The amount of O-acetyl in the sample is proportional to the amount of Vi content expressed in mg / mL. 0.5 mL of 3.6 N HCl and 1 mL of alkaline hydroxylamine solution were added to the test sample and mixed thoroughly. The mixture was kept at room temperature for 2 minutes and 0.5 mL of ferric chloride solution was added and mixed well. The absorbance was measured at 540 nm. The O-acetyl content was calculated as follows:

[0106]

[0107] Conversion factor of O-acetyl to Vi content = O-acetyl (μmol / mL) x 0.294 (25 / 0.085 / 1000) = Vi content (mg / mL)

[0108] The final sterile filtered (0.22μ) Vi-polysaccharide stock solution was freeze dried in a low temperature vacuum dryer (Freeze Dryer – FTS system). The freeze dried powders were tested for serological identification by Ouchterlony method, moisture content, protein content, nucleic acids, molecular size distribution and bacterial exotoxin content. In this study, the wells were filled with purified Vi-polysaccharide and the corresponding homologous antiserum until the meniscus just disappeared. The gel plate was incubated in a humidity chamber. The precipitin lines were observed by naked eye when the plate was seen against an illuminating light background. Figure 2 A photograph thereof is shown in , demonstrating that clear precipitin arcs were observed.

[0109] The molecular size distribution of Vi-polysaccharide was determined by using a gel permeation column with Sepharose CL-4B as stationary phase. Fractions were collected after a pore volume (Vo) corresponding to kDa 0.25 and combined. 75% of the polysaccharide eluted at 0.25 kDa. The molecular size distribution of the Salmonella typhi Vi-polysaccharide stock solution is given in the following Table 4.5. Vi was characterized by H-NMR and showed that it had 1% nucleic acid, 0.3% protein and 86% level of O-acetylation.

[0110] The results of the dried ViP stock solution obtained in a single batch are tabulated in the following Table 1.2:

[0111] test result Serological identification (Ouchterlony) Clear precipitin arcs were observed Moisture content 1.80% protein 2.5mg / g Vi polysaccharide powder Nucleic Acids 5mg / g Vi polysaccharide powder O-Acetyl Content (Herxham) 2.1mmol / g Vi polysaccharide powder Molecular size distribution 75% of the polysaccharides were eluted at 0.25 kDa Exotoxins Less than 150EU / μg Vi polysaccharide powder

[0112] Table 1.2: Results of dried Vi-polysaccharide stock solution

[0113] The above results meet all the requirements of WHO TRS 840, British Pharmacopoeia (British pharmacopeia) (2010) and Indian Pharmacopoeia (Indian pharmacopeia) (2010) standards. In this study, the requirements of WHO TRS 840 (1994) are regarded as standard specifications. The standard requirements of WHO are protein 10mg / g, nucleic acid 20mg / g, O-acetyl content is not less than 2mmol / g Vi-polysaccharide, the molecular size of 50% polysaccharide should be eluted before 0.25kDa, the identity of the immunoprecipitation method and the sterility test. According to British and European Pharmacopoeia (British and European pharmacopeia) (2007), the specification of dried Vi-polysaccharide is: protein 10mg / g, nucleic acid 10mg / g, O-acetyl 2mmol / g, no less than 50% of the polysaccharide found in the mixture (pool) containing the fraction is eluted before kDa 0.25, immunoprecipitation method is used to identify, and bacterial exotoxin test. These specifications are similar to WHO TRS 840, British Pharmacopoeia (2010) and Indian Pharmacopoeia (2010).

[0114] Example 2: Conjugation Method

[0115] Disclosed in the present invention is an effective method for conjugating purified Vi polysaccharide (ViP) to a carrier protein, such as diphtheria toxoid, tetanus toxoid, Pseudomonas aeruginosa toxoid, pertussis toxoid, Clostridium perfringens toxoid, Pseudomonas extracellular protein A, CRM197. In the present invention, purified ViP is preferably conjugated to tetanus toxoid. A variety of optional conjugation methods are used to achieve high yield conjugation. Purified ViP can be subjected to size reduction before conjugation. In the present invention, the conjugation efficiency using high molecular size (unreduced size) ViP or low molecular size (reduced size) ViP is carried out in two methods to achieve high yield of purified ViP-TT conjugate. For the conjugation of high molecular size ViP and tetanus toxoid, the concentration of ViP (unreduced in size) in the final reaction mixture should be in the range of 1 mg / ml to 10 mg / ml to obtain the desired yield of ViP-TT conjugate up to 70%-80%, while for the conjugation of low molecular size ViP and tetanus toxoid, the concentration of ViP (reduced in size) in the final reaction mixture should be in the range of 5 mg / ml to 10 mg / ml to obtain the desired yield of ViP-TT up to 70%-80%. Alternative methods for reducing the size of purified ViP are disclosed in the following section.

[0116] The novelty of the present invention is to modify Vi polysaccharides and activate them using a linker or without a linker molecule in the presence of a cross-linking agent. According to the present invention, there is no need to activate the conjugate protein. The conjugation between the activated polysaccharide and the carrier protein occurs in the presence of a cross-linking agent such as EDAC. WO2009 / 150543 teaches derivatized proteins for conjugation, wherein Vi-polysaccharides are separated from C.freundi and further conjugated with CRM197 and / or tetanus toxoid as carrier proteins. In their study, Vi and EDAC were mixed at an appropriate molar ratio (EDAC / Vi) of 0.9-1.4, and CRM197 and / or TT were optionally derivatized by treatment with ADH and EDAC. Vi was conjugated to CRM197 and TT, respectively, and the conjugated mixture was purified using polyacrylamide dextran S-1000; fractions were analyzed by SDS-PAGE, and those fractions that did not contain free protein were collected (Micoli et al., 2011). However, according to WO2009 / 150543, excess linker has been removed by dialysis, whereas in the present invention, the Vi-polysaccharide is optionally subjected to size reduction (homogenization or by microwave method) and then optionally coupled to a linker molecule or conjugation is done without any linker molecule at all. Therefore, where no linker molecule is used, no additional step of removing excess linker molecule is required. In addition, in the method involving conjugation using linker molecules, excess linker is removed by desalting and diafiltration, unlike the dialysis mentioned in WO2009 / 150543.

[0117] 2.1. Reducing the size of ViP using high pressure homogenization

[0118] ViP is a very large molecule approaching 1000 kDa. Therefore, the size of the molecule is preferably reduced to about one quarter of this large molecule to enable conjugation to a carrier protein including tetanus toxoid at low concentrations. Therefore, ViP at a concentration of 5-7.5 mg / ml was subjected to high pressure homogenization at 2-8°C, 1500 bar, and the same activity was repeated at least 45 times. As shown in the corresponding figures, the molecular size of the reduced ViP was then verified by size exclusion gel permeation chromatography. The retention time of ViP before size exclusion was 13.185 minutes ( Figure 3 ), while the retention time of ViP after size exclusion chromatography was 16.04 min ( Figure 4 ), which indicates that ViP has been reduced to a corresponding molecular size of about 200 kDa. It was verified by the Herxheimer method that the O-acetyl content of the size-reduced ViP remained the same after homogenization. Afterwards, the size-reduced ViP was additionally subjected to subsequent conjugation steps, as discussed in the following section.

[0119] 2.2. Use microwave oven to reduce the size of ViP:

[0120] Another method of reducing the size of ViP before conjugation is accomplished using a microwave oven. ViP at a concentration of 5-7.5 mg / ml in a glass bottle is placed in a microwave oven at 50%-100% power for 5-10 minutes. The microwaves generated inside the oven cause the cleavage of the long-chain glycosyl bonds of the Vi polysaccharide to reduce them to the shorter molecules required for conjugating them to the carrier protein. As shown in the corresponding figure, the molecular size of the reduced ViP is then verified by size exclusion gel permeation chromatography. The retention time of ViP before size exclusion is 13.185 minutes ( Figure 3 ), while the retention time of ViP after size exclusion chromatography was 15.18 min ( Figure 5 ), which indicates that ViP has been reduced to a corresponding molecular size of about 200 kDa. It was verified by the Herxheimer method that the O-acetyl content of the size-reduced ViP remained the same after microwave treatment. Afterwards, the size-reduced ViP was subjected to additional conjugation techniques, as discussed in the following section.

[0121] 2.3. Conjugation of Vi polysaccharide and tetanus toxoid using linkers

[0122] Purified Vi polysaccharide (reduced or not reduced in size) is partially de-O-acetylated in the presence of sodium bicarbonate, and coupled with ADH in the range of pH 6.0-7.5 using EDAC-mediated reaction. The reaction is maintained at 2-8 ° C with gentle stirring. After incubation, the reaction mixture is quenched by changing the pH to 8.0 using phosphate buffer-EDTA buffer, and phosphate is initially used and then further dialyzed using a low molecular weight cut-off membrane by MES buffer. The final mixture is concentrated, and O-acetyl content, ViP-ADH ratio, free ADH are tested.

[0123] Tetanus toxoid is concentrated and diafiltered using a low molecular weight cut-off membrane using MES buffer. The protein content of the final concentrated tetanus toxoid is tested. In order to conjugate, the Vi-polysaccharide and protein modified by EDAC coupling are used in the presence of carbodiimide condensates. The final coupled molecule is concentrated and diafiltered using a 1000kDa cut-off membrane, preferably a PES (polyethersulfone) membrane, followed by continuous buffer exchange using 20 diafiltration volumes (diavolume) of phosphate buffered saline. The polysaccharide-protein ratio, Vi content, protein content and molecular size distribution of the retentate containing purified ViP-TT are detected, and the polysaccharide-protein ratio should be within a ratio of 0.5% to 1.5%. The final conjugate stock solution is sterile filtered using a 0.22μ membrane and stored at 2-8°C.

[0124] Optionally, the final coupled molecule is concentrated and diafiltered using a 1000 kDa cut-off membrane, preferably a PES (polyethersulfone) membrane, using phosphate buffered saline and subsequently loaded into a gel permeation column (agarose cross-linked beads). The fractions collected within a ratio of 0.5% to 1.5% are mixed together, concentrated and tested for polysaccharide-protein ratio, Vi content, protein content and molecular size distribution. The final conjugate stock solution is sterile filtered using a 0.22 μ membrane and stored at 2-8° C.

[0125] The molecular size distribution of the Vi polysaccharide conjugate stock solution of the present invention is given in Table 2.1. The molecular size of the ViP-TT conjugate obtained in the present invention is 0.3 kDa; when compared with the results obtained in the previous study of the conjugate ViP-TT, the molecular size distribution of the given conjugate is <0.1 kDa. This means that a molecular size distribution of 0.3 kDa indicates an optimal filterable size, which allows proper filtration of ViP-TT while providing better immunogenicity for the conjugate vaccine compared to other lower molecular size distributions provided in the prior art. Larger molecular sizes predict better immunogenicity, but it is also crucial to limit the molecular size to an appropriate size that allows filtration of ViP-TT. Therefore, due to this molecular size distribution of 0.3 kDa, as claimed in the present invention, only one single injection of the typhoid conjugate vaccine is sufficient to constitute a complete vaccination schedule against typhoid fever caused by Salmonella typhi. The prior art stipulates more than one injection, preferably three doses, in the case of conjugate vaccines against typhoid fever with a lower molecular size distribution.

[0126] The total and free (unbound) Vi polysaccharide were determined by HPAEC-PAD analysis. In the present method, the Vi conjugate produced 75% of Vi polysaccharide conjugate when eluted at kDa 0.30, giving good polydispersity and produced Vi content 0.56 mg / ml, free ViP 5%, protein content 0.25 mg / ml, ViP-protein ratio 1.05, no free protein peak was detected and sterility was found to be acceptable (refer to Table 2.1). The present method was carried out with an initial batch scale of 10 gm of ViP, producing 8 liters of ViP conjugate stock solution with a Vi conjugate concentration of 0.9 mg / ml-1.0 mg / ml, which produced 7-8 gm of ViP-TT conjugate, giving a yield of 70%-80%.

[0127]

[0128] Table 2.1: Results of ViP-TT conjugate stock solutions with linkers

[0129] Figure 6 to Figure 7HPLC chromatograms showing Vi-polysaccharide and ViP-TT conjugate stock solutions with linkers at different stages. All presented HPLC spectra clearly demonstrate the conjugation effectiveness of the present method.

[0130] As described above, the conjugation method using the linker molecule ADH to obtain purified ViP-TT conjugate vaccine antigen for the preparation of a conjugate vaccine preparation against typhoid fever caused by Salmonella typhi can be summarized into the following steps:

[0131] a. Cultivating in a fed-batch mode using a feed medium to obtain purified ViP, the feed medium comprising feeding a solution containing glucose in a concentration range of 1 mg / mL to 2 mg / mL, pH maintained in the range of 6.90 to 7.20 and dissolved oxygen level maintained between 40% and 60%, wherein together with the feed medium, an ammonia solution (50%) is supplied as a nitrogen source;

[0132] b. Optionally reducing the size of ViP by subjecting ViP at a concentration of 5-7.5 mg / ml to high pressure homogenization at 1500 bar, 2-8° C. and repeating the same activity at least 45 times, or by microwave oven, so as to obtain a purified ViP of a corresponding molecular size of approximately 250 kDa;

[0133] c. treating the purified ViP of step (a) or step (b) with a cross-linking agent EDAC;

[0134] d. activating the ViP of step (c) with the linker molecule ADH in the presence of EDAC;

[0135] e. treating the activated ViP linked to the linker molecule ADH of step (d) with a carrier protein in the presence of EDAC at a concentration of 1 mg / ml to 5 mg / ml of purified ViP of ˜900 kDa or at a concentration of 5 mg / ml to 7.5 mg / ml of purified ViP of ˜250 kDa to form a Vi-polysaccharide-carrier protein conjugate;

[0136] f. The Vi-polysaccharide-carrier protein conjugate of step (e) was diafiltered by serial buffer exchange with phosphate buffered saline using a 1000 kDa membrane to obtain purified ViP-carrier protein vaccine antigen.

[0137] 2.4. Conjugation of Vi-polysaccharide and tetanus toxoid without linker:

[0138] Purified Vi polysaccharide (size reduced or not) is placed in a buffer of MES (2-morpholinoethane sulfonic acid) or PBS or in normal saline at pH varying from 5.0 to 9.0 (to be precise pH 6-7.5) and the concentration of polysaccharide varies from 1.0 mg to 20 mg / ml (5 mg / ml). Protein is placed in a buffer such as MES or PBS or in normal saline at pH varying from 6.0 to 9.0 (to be precise pH 6-7.5) at different concentrations ranging from 2.0 mg / ml to 20.mg / ml (10 mg / ml). The ratio of ViP to protein should be between 1:1 to 1:3, meaning that if a total of 1 gm of ViP is placed, then there should be 1 gm to 3 gm of protein that is subjected to conjugation. The conjugation is performed at 2°C-8°C to effectively control the reaction rate compared to room temperature. At higher temperatures, the rate of conjugation is very fast. It is not preferred to expose the polysaccharide to higher temperatures because there is a possibility of aggregation of the conjugated polysaccharide-protein molecules after the conjugate is formed at higher temperatures. This will increase the size of the molecule, which will make it difficult to further purify the conjugate protein in subsequent steps. Therefore, conjugation is preferably at 2-8°C. ViP and TT are added together at different concentrations in any buffer of different pH conditions described above and incubated for conjugation. The incubation time at room temperature (25°C) varies between 15-45 minutes, and the incubation time at 2-8°C is between 1 hour and 2 hours, however, when following the conjugation method using ADH (using a linker), the incubation time required for conjugation is at least 2-4 hours at 2°C-8°C. Therefore, compared with the conjugation using a linker, the total reaction time is also reduced according to this conjugation method without a linker.

[0139] The final coupled molecule is concentrated and diafiltered using a 1000 kDa cut-off membrane, preferably a PES (polyethersulfone) membrane, followed by serial buffer exchange using 20 diafiltration volumes of phosphate buffered saline. The retentate containing the purified ViP-TT is tested for polysaccharide-protein ratio, Vi-content, protein content and molecular size distribution, the polysaccharide-protein ratio should be within a ratio of 0.5%-1.5%. The final conjugate stock solution is sterile filtered using a 0.22μ membrane and stored at 2-8°C.

[0140] Optionally, the final coupled molecule is concentrated and diafiltered using phosphate buffered saline using a 1000 kDa cut-off membrane, preferably a PES (polyethersulfone) membrane, and subsequently loaded into a gel permeation column (agarose cross-linked beads). The fractions collected within a ratio of 0.5% to 1.5% are mixed together, concentrated and tested for polysaccharide-protein ratio, Vi content, protein content, and molecular size distribution. The final conjugate stock solution is sterile filtered using a 0.22 μ membrane and stored at 2-8° C.

[0141] The present conjugation process without any linker molecule was performed using 10 gm of initial batch scale of ViP, producing 8 liters of ViP conjugate stock solution at 0.9 mg / ml-1.0 mg / ml Vi conjugate concentration, which produced 7-8 gm of ViP-TT conjugate, giving 70%-80% yield.

[0142]

[0143]

[0144] Table 2.2.: Results of ViPs-TT conjugate stock solution without linker

[0145] The crude conjugate is then obtained by GPC, TFF, ion exchange or HIC. The conjugate meets all required pharmacopeia specifications and is further sterile filtered. Figures 8 to 9 HPLC chromatograms showing Vi-polysaccharide and ViP-TT conjugate stock solutions without linker at different stages. All presented HPLC spectra clearly demonstrate the conjugation efficiency of the present method.

[0146] The conjugation method to obtain the purified ViP-TT conjugate vaccine antigen for the preparation of the conjugate vaccine preparation against typhoid fever caused by Salmonella typhi as described above without using any linker molecule ADH can be summarized in the following steps:

[0147] a. performing a fed-batch mode culture using a feed medium to obtain purified ViP, the feed medium comprising feeding a solution containing glucose in a concentration range of 1 mg / mL to 2 mg / mL, the pH being maintained in the range of 6.90 to 7.20, and the dissolved oxygen level being maintained between 40% and 60%, wherein together with the feed medium, an ammonia solution (50%) is supplied as a nitrogen source;

[0148] b. Optionally reducing the size of ViP by subjecting ViP at a concentration of 5-7.5 mg / ml to high pressure homogenization at 1500 bar, 2-8° C. and repeating the same activity at least 45 times, or by microwave oven, to obtain purified ViP with a corresponding molecular size of approximately 250 kDa;

[0149] c. treating the purified ViP of step (a) or step (b) with a cross-linking agent EDAC;

[0150] d. treating the carrier protein with the ViP of step (c) in the presence of the cross-linking agent EDAC at a concentration of 1 mg / ml to 5 mg / ml of purified ViP of ˜900 kDa or at a concentration of 5 mg / ml to 7.5 mg / ml of purified ViP of ˜250 kDa to form a Vi-polysaccharide-carrier protein conjugate;

[0151] e. The ViP-carrier protein conjugate of step (d) was diafiltered by serial buffer exchange with phosphate buffered saline using a 1000 kDa membrane.

[0152] Linker molecules, such as ADH, contain terminal amino groups at both ends. The Vi native polysaccharide, which is further reduced in size prior to conjugation, naturally contains abundant functional carboxyl groups (-COOH). Carrier proteins, such as tetanus toxoid, contain amino groups (-NH 2 In the case of conjugating ViP to a carrier protein with the aid of a linker molecule ADH, this is accomplished in the presence of a cross-linking agent such as EDAC, wherein the -COOH group of ViP should be coupled to one of the -NH groups of the ADH linker via one of the ends of the ADH linker. 2 The activated ViP is coupled to the linker ADH, connected at one end of the ADH molecule through a -CONH bond. The other end of the ADH molecule remains free to further bond with the -COOH group present in the carrier protein under a suitable concentration and temperature range. Therefore, the activated ViP-ADH reacts again with the carrier protein in the presence of the crosslinker EDAC, which allows the -NH 2 It is able to bind to the -COOH group of the carrier protein molecule, thereby forming an effective bridge between the Vi-polysaccharide and the carrier protein. Therefore, in this method, it is necessary to remove the excess linker after treating ViP with ADH, and remove the excess linker again after treating ViP-ADH to the carrier protein. In addition, EDAC needs to be used twice in this method.

[0153] On the other hand, when the method of conjugating ViP to a carrier protein without using any linker molecule is followed, since ViP has a free -COOH group and the carrier protein has a free –NH 2 The -COOH group of ViP is then bonded to the –NH group of the carrier protein by treatment in the presence of a cross-linking agent such as EDAC. 2 Direct conjugation is possible. The entire reaction is completed in one step, which minimizes the use of excess EDAC and reduces the time to complete the conjugation of ViP to the carrier protein. Since all carrier proteins contain free –NH 2Group, and ViP also has free-COOH, so it is possible to conjugate any carrier protein such as diphtheria toxoid, tetanus toxoid, CRM197, etc. with Vi-polysaccharide by this method. Therefore, for conjugating ViP to carrier protein, it is not necessary to use any linker molecule (ADH). The advantage of not using the conjugation of a linker is reflected in the stability of the conjugate, because there is no any connecting molecule bridge with ADH between ViP and carrier protein. Due to the increase in the strength of the ViP-carrier protein conjugate (in this case ViP-TT) molecule in the absence of any connecting bridge, this ensures better stability. The other degradation of ViP-TT is also reduced to a very high degree. And in this method, it is quite easy to operate and perform the experiment. The total EDAC amount required is reduced to about 50%, and it is only operated once instead of being used twice in the case of the ADH linker method. (EDAC is a stimulant that may cause protein coagulation after long-term exposure). In addition, GPC columns or TFF systems are not required to remove excess joints. With the reduced number of steps, we are able to minimize the loss of ViP for conjugation to any carrier protein (e.g. TT) since the purification steps associated with the ViP-ADH ligation are omitted. The following table lists the total time taken to complete the entire conjugation experiment with reduced steps and with and without the linker molecule.

[0154] Total time spent in the entire conjugation experiment:

[0155]

[0156] Table 2.3: Comparison of time taken to complete the conjugation process.

[0157] Example 3: Vaccine formulation and stability.

[0158] A typical single dose of the typhoid conjugate vaccine formulation claimed in the present invention contains from 15 micrograms (μg) to 25 μg of Vi-TT conjugate as antigen, dissolved in saline to make a total volume of 0.5 ml for one injection as a complete vaccination schedule.

[0159] The vaccine preparation based on the present invention can also be used in the form of multi-dose vials.Multi-dose vials can be 5 doses (for 5 different vaccine recipients / experimenters / expected vaccine recipients) or 10 doses (for 10 different vaccine recipients / experimenters / expected vaccine recipients).In the case of multi-dose vials, preservatives are added to the vaccine preparation to avoid the contamination of the vaccine preparation for repeatedly piercing the vial to vaccinate 5-10 different children by the same vaccine multi-dose vial vaccine.The multi-dose vials of the ViP-TT typhoid conjugate vaccine preparation of the present invention use a unique preservative 2-phenoxyethanol, which does not contain mercuric chloride and thimerosal.The current situation in the art has reported the defect of using conventional preservatives such as mercuric chloride and thimerosal that act on carcinogenicity.Therefore, the use of this unique preservative 2-phenoxyethanol overcomes the defect of conventional preservatives mercuric chloride and thimerosal.The details of multi-dose vials and their preparations are made into tables below:

[0160]

[0161] Table 3.1: Vaccine formulations for single-dose and multi-dose vials

[0162] The stability of BBIL's ViP-TT conjugate vaccine has been studied in detail and confirmed for 3 years. The ViP Typhoid conjugate ViP-TT vaccine was subjected to stability studies at both accelerated storage conditions (25°C ± 2°C) for 6 months and real-time storage conditions (2°C to 8°C) for 36 months and the test results obtained were found to be within the limits and meet the required specifications (Tables 3.2 to 3.5).

[0163]

[0164] Table 3.2: Typbar-TCV (conjugated with linker molecules) TM Stability study at 2°C to 8°C (25 μg per 0.5 ml dose of Vi-TT)

[0165]

[0166] Table 3.3: Typbar-TCV (conjugated with linker molecules) TM Stability study at 25℃±2℃ (25μg per 0.5ml dose of Vi-TT)

[0167]

[0168]

[0169] Table 3.4: Typbar-TCV (without linker molecule conjugation) TMStability study at 2°C to 8°C (25 μg per 0.5 ml dose of Vi-TT)

[0170]

[0171] Table 3.5: Typbar-TCV (without linker molecule conjugation) TM Stability study at 25℃±2℃ (25μg per 0.5ml dose of Vi-TT)

[0172] Example 4: Clinical Trial

[0173] The final Vi-polysaccharide-tetanus toxin conjugate stock solution was formulated and tested in Balb / c mice for immunogenicity compared to the native polysaccharide vaccine. Challenge studies were conducted to evaluate the protective efficacy of the vaccine, and preclinical trials were conducted in laboratory animals to determine abnormal, acute and systemic toxicity. In addition, the efficacy of the test vaccine Vi capsular polysaccharide-tetanus toxoid conjugate (Vi-TT) was studied at two different concentration doses (15 μg and 25 μg per dose), and both concentrations were shown to induce protective antibodies in infants, children and adults. The comparison with the reference vaccine (Salmonella typhi Vi-polysaccharide vaccine) was evaluated. ) Immunogenicity and safety of typhoid Vi capsular polysaccharide-tetanus toxoid protein conjugate compared with BBIL's Vi-TT conjugate vaccine.

[0174] Phase-II: A total of 100 subjects will be enrolled to evaluate the efficacy of the vaccine compared to the reference Typhoid Vi capsular polysaccharide vaccine in healthy adolescents aged 13 to 17 years, children aged 6 to 12 years, and children aged 2 to 5 years. Safety and immunogenicity of the Vi typhoid capsular polysaccharide-TT protein conjugate vaccine compared to the Vi typhoid capsular polysaccharide-TT protein conjugate vaccine. The study showed that the experimental vaccine Vi capsular polysaccharide-tetanus toxoid conjugate (Vi-TT) was superior to the reference Vi typhoid capsular polysaccharide vaccine in terms of immunogenicity and reactogenicity in all age groups. When compared with the previous vaccination The geometric mean of Vi IgG in ELISA units per milliliter (EU / ml) was increased by 80%, 100% and 70% respectively, up to a more than four-fold increase compared to sera from the control group.

[0175] The experimental vaccine of Vi Typhoid Capsular Polysaccharide-Tetanus Toxoid Conjugate Vaccine (Vi-TT) was administered as a single injection to adolescents aged 13-17 years and the age group of 2-6 years at 25 micrograms / dose. When compared with the previous vaccinated sera, in both age groups, the geometric mean 100% of Vi IgG EU / ml increased by more than four times. In contrast, the age group of 2-5 years was injected with 25 μg / dose in two injections. The time interval for the administration of the second injection was 6 weeks each. When compared with the previous vaccinated sera, in this age group, the geometric mean 100% of Vi IgG EU / ml increased by more than four times.

[0176] Another group was designed to administer 15 μg / dose as two injections to the age group between 2-5 years old. The time interval for administering the second injection was each 6 weeks. When compared to the previous vaccinated serum, the geometric mean 100% of Vi IgG EU / ml in the 2-5 year old age group each increased by more than four times.

[0177] All test groups with 25 μg as a single injection, 25 μg per dose as two injections and 15 μg per dose as two injections showed 100% seroconversion. In all age groups, the antibodies in response to the Vi-polysaccharide-tetanus toxoid protein conjugate vaccine were superior to the reference natural polysaccharide vaccine. Therefore, it can be concluded that BBIL's test vaccine Typhoid Vi Capsular Polysaccharide Tetanus Toxoid Conjugate (Vi-TT) vaccine is superior to the already commercially available reference vaccine BBIL. Excellent.

[0178] Phase III Subject Number Details: A total of 981 subjects were assigned to the Typhoid Conjugate ViP-TT vaccine and the Reference vaccine To evaluate the typhoid Vi-polysaccharide-TT conjugate vaccine ViP-TT (Typbar-TCV TM ) compared to the common typhoid Vi-polysaccharide vaccine ( The immunogenicity and safety of the BBIL typhoid conjugate ViP-TT vaccine and the common typhoid Vi-polysaccharide vaccine ( The geometric mean titer (GMT) and 4-fold seroconversion percentage of the Typhoid-TT conjugate vaccine were compared between the three age groups (6 months to 2 years, >2 to <15 years, and 15 to 45 years) compared to the reference vaccine. The GMT of the Typhoid-TT conjugate vaccine in subjects in the age groups of 6 months to 2 years, >2 years to <15 years, and 15 to 45 years was 1952.03 EU / ml, 1555.51 EU / ml, and 812.97 EU / ml Typhoid anti-Vi IgG antibodies by ELISA on Day 42, respectively. The seroconversion (4-fold titer rise) percentage of the Typhoid-TT conjugate vaccine in subjects in the age groups of 6 months to 2 years, >2 years to <15 years, and 15 to 45 years was 98.05%, 99.17%, and 92.13% seroconversion on Day 42, respectively. Fig.13 ).

[0179]

[0180] Table 4.1: Typbar-TCV TM Phase III clinical trial data

[0181] In the 2 to <15 years age group, Typbar-TT conjugate Typbar-TCV TM Vaccines and typhoid vaccine The GMT of the groups on day 42 were 1555.51EU / ml and 426.63EU / ml Typhoid anti-Vi IgG antibodies by ELISA (p=0.00001). TM Vaccines and typhoid vaccine The percentages of seroconversion (4-fold titer rise) on day 42 were 99.17% and 94.86%, respectively (p=0.0086).

[0182] In the 15 to 45 age group, Typbar-TCV TM Vaccines and typhoid vaccine The GMTs of the groups were 812.97 EU / ml and 376.81 EU / ml Typhoid anti-Vi IgG antibodies by ELISA on day 42 (p=0.0001). TM Vaccines and typhoid vaccine The percentages of seroconversion (4-fold titer rise) on day 42 in the groups were 92.13% and 89.01%, respectively (p=0.4737).

[0183] The advantage of the Typhoid-TT (ViP-TT) conjugate vaccine was that the GMT after vaccination was 3.16 times that of the common polysaccharide vaccine. The titer ratio of the GMT evaluated after vaccination with the Typhoid conjugate vaccine (test) was 3.53 times that of the common polysaccharide vaccine (reference). For seroconversion, the Typhoid conjugate vaccine was significantly superior to the common polysaccharide vaccine by a margin of 0.016%.

[0184] The following describes the reference vaccine Compare BBIL Typbar-TCV TM Overview of Phase III clinical trial data of ViP-TT conjugate vaccine ( Fig.12 and Fig.13 ), and also provides the following table with Peda Typh TM Comparison:

[0185]

[0186] Table 4.2: Typbar-TCV TM and

[0187] Example 5: Interference study of TCV and measles

[0188] Typbar-TCV TM It is a preparation of Vi-polysaccharide vaccine conjugated to a tetanus toxoid carrier protein. It has been demonstrated that children receiving the Vi conjugate vaccine achieve and maintain higher levels of anti-Vi IgG serum antibodies than those receiving the ordinary Vi-polysaccharide vaccine. Typbar-TCV is proposed in the immunization schedule to be administered between the 6th and 24th months of a child's life, and preferably within the 9th month. TM (ViP-TT conjugate vaccine). Since measles vaccination is also completed at the same time, combining the two vaccines and administering them as a single injection will provide additional benefits. In order to be able to achieve this goal, it is necessary to explore the interference of the two vaccines with each other's biological and chemical properties. Based on the above proposals, a study was designed to use liquid Typbar-TCV TM (ViP-TT conjugate vaccine) Lyophilized measles vaccine was reconstituted and tested for O-acetyl content at 0, 4 and 12 hours after incubation at 25°C (for Typbar-TCV TM ) and cytopathic effect assay (for measles virus). Physiological chemical and biological parameters of both vaccines were checked to be within specifications at the stated temperature and time points.

[0189] This study provides an overview of laboratory findings with reconstituted vaccine preparations over a short period of time.

[0190]

[0191] Table 5.1: Specifications for typhoid conjugate vaccine and measles vaccine

[0192] Test performed: O-acetyl content by Herxheimer's method

[0193] Vi-polysaccharide is a linear homopolymer composed of (1-4)-20-acetamido-2-deoxy-α-D-galacturonic acid O-acetylated at carbon-3. The O-acetyl content of purified Vi-polysaccharide is important for the immunogenicity of Vi and can be measured by using the Hirsch method.

[0194]

[0195] Table 5.2: O-acetyl content by Hershel method

[0196] result:

[0197] The Typbar-TCV incubated at 25°C was analyzed by the Hershel method TM (ViP-TT conjugate vaccine) O-acetyl content of reconstituted measles vaccine. As a control, Typbar-TCV maintained at 2-8°C was also analyzed. TM (ViP-TT conjugate vaccine) and Typbar-TCV at 25°C at the start of time point TM (ViP-TT conjugate vaccine). As expected, the O-acetyl content of the control sample at 2-8°C and 25°C was close to the initial value. The O-acetyl content of the combination vaccine (measles + TCV) was higher than the acceptance criterion (0.151 μmol / dose) at 0 hours. It decreased over time at 4 hours and 8 hours (0.086 μmol / dose and 0.058 μmol / dose), which were within the acceptance criterion, but comparable to the Typbar-TCV alone at 2-8°C and 25°C. TM The values ​​are different.

[0198] Tests performed: Potency testing by cytopathic effect (CPE) method

[0199] Measles vaccine is a live attenuated vaccine. To determine the titer of measles vaccine, logarithmic dilutions were prepared and each logarithmic dilution was inoculated into the Vero cell line in 8 replicates and incubated for 7-8 days and examined for the presence or absence of cytopathic effect. The virus titer was calculated by the Spearman Karber formula. The results are as follows:

[0200]

[0201] Table 5.3: Potency testing by cytopathic approach

[0202] result: From the results it was observed that the measles vaccine was found to be stable for 12 hours when reconstituted with dilutions of the measles vaccine and when reconstituted with Typbar-TCV TM (ViP-TT conjugate vaccine) Upon reconstitution it was stable for 4 hours and declined between 4 and 8 hours.

Claims

1. A method for preventing infection caused by Salmonella typhi ( Salmonella typhi ), the vaccine preparation comprising partially de-O-acetylated capsular Vi-polysaccharide (ViP) of Salmonella typhi, the capsular Vi-polysaccharide (ViP) being conjugated to tetanus toxoid as a carrier protein to form a Vi-polysaccharide (ViP)-tetanus toxoid conjugate vaccine antigen, in, The Vi-polysaccharide (ViP)-tetanus toxoid conjugate vaccine antigen comprises an activated partially de-O-acetylated capsular Vi-polysaccharide (ViP) conjugated to a tetanus toxoid, wherein the tetanus toxoid is not derivatized with ADH and no free ADH is attached to the tetanus toxoid; wherein the vaccine preparation contains 5 µg to 25 µg of the conjugated vaccine antigen per dose; and wherein a single dose of the vaccine formulation constitutes a complete vaccination schedule by only one injection, eliciting the desired T-dependent immune response against Salmonella Typhi, wherein said elicitation includes eliciting a T-dependent immune response against Salmonella Typhi in children under two years of age; The conjugate vaccine antigen is prepared by a method comprising the following steps: (a) carrying out a culture in a fed-batch mode using a feed medium to obtain purified Vi-polysaccharide (ViP), the feed medium comprising feeding a solution containing glucose in a concentration range of 1 mg / mL to 2 mg / mL, the pH being maintained in a range of 6.90 to 7.20 and the dissolved oxygen level being maintained between 40% and 60%, wherein together with the feed medium, a 50% ammonia solution is supplied as a nitrogen source; (b) optionally reducing the size of the Vi-polysaccharide (ViP), wherein said Vi-polysaccharide (ViP) at a concentration of 5-7.5 mg / ml is subjected to high pressure homogenization at 1500 bar, 2-8° C. and the same activity is repeated at least 45 times, or by microwave oven, to obtain a purified Vi-polysaccharide (ViP) of a corresponding molecular size of 250 kDa; (c) treating the purified Vi-polysaccharide (ViP) of step (a) or step (b) with a cross-linking agent EDAC; (d) treating tetanus toxoid with the Vi-polysaccharide (ViP) of step (c) in the presence of the cross-linking agent EDAC at a concentration of 1 mg / ml to 5 mg / ml of 900 kDa purified Vi-polysaccharide (ViP) or at a concentration of 5 mg / ml to 7.5 mg / ml of 250 kDa purified Vi-polysaccharide (ViP) to form a Vi-polysaccharide (ViP)-tetanus toxoid conjugate; (e) diafiltering the Vi-polysaccharide (ViP)-tetanus toxoid conjugate of step (d) by continuous buffer exchange with phosphate buffered saline using a 1000 kDa membrane to obtain a purified Vi-polysaccharide (ViP)-tetanus toxoid conjugate vaccine antigen.

2. The vaccine formulation of claim 1, wherein the conjugated vaccine antigen is present in the vaccine formulation at a concentration of 25 μg per dose.

3. The vaccine formulation according to claim 1 or 2, wherein the yield of the Vi-polysaccharide (ViP)-tetanus toxoid conjugate ranges from 70% to 80%.

4. The vaccine formulation according to claim 1, wherein when administered to a patient in conjunction with a measles vaccine formulation, does not show any antigenic interference between the Vi-polysaccharide (ViP)-tetanus toxoid conjugate antigen and measles antigen.

5. The vaccine formulation of claim 1, wherein the vaccine formulation is stable at 2°C-8°C for 3 years and at 25°C for at least 6 months.

6. The vaccine formulation according to claim 1, wherein the vaccine formulation further comprises 2-phenoxyethanol as a stabilizer in the case of a multi-dose vial.

7. The vaccine formulation according to claim 1, wherein the seroconversion percentage of the vaccine formulation is between 98% and 100% in the case of the age group of 6 months to 24 months, between 99% and 100% in the case of the age group of 2 years to 15 years, and between 90% and 100% in the case of the age group of 15 years to 45 years, thereby providing a four-fold increase in seroconversion on day 42 after vaccination.

8. A method for preparing a Salmonella typhi Vi-polysaccharide (ViP)-tetanus toxoid conjugate vaccine antigen, the method The following steps are involved: (a) carrying out a culture in a fed-batch mode using a feed medium to obtain purified Vi-polysaccharide (ViP), the feed medium comprising feeding a solution containing glucose in a concentration range of 1 mg / mL to 2 mg / mL, the pH being maintained in a range of 6.90 to 7.20 and the dissolved oxygen level being maintained between 40% and 60%, wherein together with the feed medium, a 50% ammonia solution is supplied as a nitrogen source; (b) optionally reducing the size of the Vi-polysaccharide (ViP), wherein said Vi-polysaccharide (ViP) at a concentration of 5-7.5 mg / ml is subjected to high pressure homogenization at 1500 bar, 2-8° C. and the same activity is repeated at least 45 times, or by microwave oven, to obtain a purified Vi-polysaccharide (ViP) of a corresponding molecular size of 250 kDa; (c) treating the purified Vi-polysaccharide (ViP) of step (a) or step (b) with a cross-linking agent EDAC; (d) treating tetanus toxoid as a carrier protein with the Vi-polysaccharide (ViP) of step (c) in the presence of the cross-linking agent EDAC at a concentration of 1 mg / ml to 5 mg / ml of 900 kDa purified Vi-polysaccharide (ViP) or at a concentration of 5 mg / ml to 7.5 mg / ml of 250 kDa purified Vi-polysaccharide (ViP) to form a Vi-polysaccharide (ViP)-tetanus toxoid conjugate; (e) diafiltering the Vi-polysaccharide (ViP)-tetanus toxoid conjugate of step (d) by continuous buffer exchange with phosphate buffered saline using a 1000 kDa membrane to obtain a purified Vi-polysaccharide (ViP)-tetanus toxoid conjugate vaccine antigen.

9. The method according to claim 8, wherein the yield of the Vi-polysaccharide (ViP)-tetanus toxoid conjugate ranges from 70% to 80%.

10. Use of a partially de-O-acetylated capsular Vi-polysaccharide (ViP) of Salmonella Typhi conjugated to a tetanus toxoid in the preparation of a vaccine formulation for the prevention of typhoid fever caused by Salmonella Typhi in children less than 2 years of age, said prevention constituting a complete vaccination schedule by only one injection, wherein said partially de-O-acetylated capsular Vi-polysaccharide (ViP) comprises activated partially de-O-acetylated capsular Vi-polysaccharide (ViP), wherein said tetanus toxoid has not been derivatized with ADH and no free ADH is attached to said tetanus toxoid, and said vaccine formulation is sufficient to elicit the desired T-dependent immune response against Salmonella Typhi. wherein the partially de-O-acetylated Salmonella typhi capsular Vi-polysaccharide (ViP) conjugated to tetanus toxoid is prepared by a method comprising the following steps: (a) carrying out a culture in a fed-batch mode using a feed medium to obtain purified Vi-polysaccharide (ViP), the feed medium comprising feeding a solution containing glucose in a concentration range of 1 mg / mL to 2 mg / mL, the pH being maintained in a range of 6.90 to 7.20 and the dissolved oxygen level being maintained between 40% and 60%, wherein together with the feed medium, a 50% ammonia solution is supplied as a nitrogen source; (b) optionally reducing the size of the Vi-polysaccharide (ViP), wherein said Vi-polysaccharide (ViP) at a concentration of 5-7.5 mg / ml is subjected to high pressure homogenization at 1500 bar, 2-8° C. and the same activity is repeated at least 45 times, or by microwave oven, to obtain a purified Vi-polysaccharide (ViP) of a corresponding molecular size of 250 kDa; (c) treating the purified Vi-polysaccharide (ViP) of step (a) or step (b) with a cross-linking agent EDAC; (d) treating the carrier tetanus toxoid with the Vi-polysaccharide (ViP) of step (c) in the presence of the cross-linking agent EDAC at a concentration of 1 mg / ml to 5 mg / ml of 900 kDa purified Vi-polysaccharide (ViP) or at a concentration of 5 mg / ml to 7.5 mg / ml of 250 kDa purified Vi-polysaccharide (ViP) to form a Vi-polysaccharide (ViP)-tetanus toxoid conjugate; (e) diafiltering the Vi-polysaccharide (ViP)-tetanus toxoid conjugate of step (d) by continuous buffer exchange with phosphate buffered saline using a 1000 kDa membrane to obtain a purified Vi-polysaccharide (ViP)-tetanus toxoid conjugate vaccine antigen.

11. The use according to claim 10, wherein the Vi-polysaccharide (ViP)-tetanus toxoid conjugate vaccine antigen is present in a concentration of 5 µg to 25 µg per dose.

12. The use according to claim 10, wherein the Vi-polysaccharide (ViP)-tetanus toxoid conjugate vaccine antigen is present at a concentration of 25 μg per dose.

13. The use according to claim 10, wherein the vaccine formulation is stable at 2°C-8°C for 3 years and at 25°C for at least 6 months.

14. The use according to claim 10, wherein the vaccine formulation further comprises 2-phenoxyethanol as a stabilizer in the case of multi-dose vials.

15. Use according to claim 10, wherein the seroconversion percentage of the vaccine formulation is between 98% and 100% in the case of the age group of 6 to 24 months, between 99% and 100% in the case of the age group of 2 to 15 years, between 90% and 100% in the case of the age group of 15 to 45 years, thereby providing a four-fold increase in seroconversion on day 42 after vaccination.

16. A combination vaccine preparation comprising the following antigens: a. The Vi-polysaccharide (ViP)-tetanus toxoid conjugate vaccine antigen defined in the vaccine formulation of claim 1; b. Measles antigen; There is no antigenic interference between Vi-polysaccharide (ViP)-tetanus toxoid and measles antigens for the prevention of typhoid fever caused by Salmonella Typhi and measles virus, wherein the vaccine formulation constitutes a complete immunization schedule with only one injection, sufficient to induce the desired T-dependent immune response against Salmonella Typhi, including in children less than two years of age.

17. The combination vaccine formulation according to claim 16, wherein the Vi-polysaccharide (ViP)-tetanus toxoid conjugate vaccine antigen is present at a concentration of 25 μg per dose.